Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations

    August 2023 in “ EClinicalMedicine ”
    A. D’Arienzo, Annarita Verrazzo, Martina Pagliuca, Fabiana Napolitano, Sara Parola, Martina Viggiani, Roberta Caputo, Fabio Puglisi, Mario Giuliano, Lucia Del Mastro, Grazia Arpino, Michelino De Laurentiis, Filippo Montemurro
    TLDR ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
    Antibody-drug conjugates (ADCs) are a promising class of cancer treatments that target tumors more precisely, reducing systemic toxicity. Despite their generally good tolerance, they can cause adverse reactions such as neutropenia, nausea, vomiting, alopecia, diarrhea, left ventricular dysfunction, and ILD/pneumonitis. This review compiles the latest evidence on these toxicities in breast cancer treatment, offering prophylaxis protocols and management strategies to prevent or address these issues, thereby avoiding premature treatment discontinuation or improper dose reduction.
    Discuss this study in the Community →

    Cited in this study

    2 / 2 results